2024
Vaccine-induced human monoclonal antibodies to PfRH5 show broadly neutralizing activity against P. falciparum clinical isolates
Thiam L, McHugh K, Ba A, Li R, Guo Y, Pouye M, Cisse A, Pipini D, Diallo F, Sene S, Patel S, Thiam A, Sadio B, Mbengue A, Vigan-Womas I, Sheng Z, Shapiro L, Draper S, Bei A. Vaccine-induced human monoclonal antibodies to PfRH5 show broadly neutralizing activity against P. falciparum clinical isolates. Npj Vaccines 2024, 9: 198. PMID: 39448626, PMCID: PMC11502735, DOI: 10.1038/s41541-024-00986-x.Peer-Reviewed Original ResearchP. falciparum clinical isolatesClinical isolatesNext-generation sequencingEarly clinical studiesDose-dependent inhibitionGrowth inhibition activitySingle B cellsOccurrence of novel mutationsNext-generation sequencing analysisBlood-stageNo significant differencePfRH5MAb combinationsNovel mutationsClinical studiesNeutralizing activityAntibody susceptibilityIgG responsesPre-clinicalGenotype/phenotype relationshipsMonoclonal antibodiesVaccine alleleGenetic diversitySignificant differenceMAb
2023
Cytochrome P450 3A4 suppression by epimedium and active compound kaempferol leads to synergistic anti-inflammatory effect with corticosteroid
Li K, Yu X, Maskey A, Musa I, Wang Z, Garcia V, Guo A, Yang N, Srivastava K, Dunkin D, Li J, Guo L, Cheng Y, Yuan H, Tiwari R, Li X. Cytochrome P450 3A4 suppression by epimedium and active compound kaempferol leads to synergistic anti-inflammatory effect with corticosteroid. Frontiers In Pharmacology 2023, 13: 1042756. PMID: 36793921, PMCID: PMC9922998, DOI: 10.3389/fphar.2022.1042756.Peer-Reviewed Original ResearchTNF-α productionEffect of EpimediumAnti-inflammatory effectsCYP3A4 mRNA expressionDose-dependent mannerCYP3A4 activityCYP3A4 mRNASynergistic anti-inflammatory effectsMRNA expressionCYP3A4 functionTNF-α levelsAnti-inflammatory functionsIL-8 productionCompound kaempferolDose-dependent inhibitionCytochrome P450 3A4Human hepatocyte carcinomaMurine macrophage cell lineIL-8Inflammatory conditionsMacrophage cell lineCorticosteroidsCYP 3A4Major drugsCell cytotoxicity
2022
Ovarian and uterine carcinosarcomas are sensitive in vitro and in vivo to elimusertib, a novel ataxia-telangiectasia and Rad3-related (ATR) kinase inhibitor
Manavella D, McNamara B, Harold J, Bellone S, Hartwich T, Yang-Hartwich Y, Mutlu L, Zipponi M, Demirkiran C, Verzosa M, Altwerger G, Ratner E, Huang G, Clark M, Andikyan V, Azodi M, Schwartz P, Dottino P, Choi J, Alexandrov L, Buza N, Hui P, Santin A. Ovarian and uterine carcinosarcomas are sensitive in vitro and in vivo to elimusertib, a novel ataxia-telangiectasia and Rad3-related (ATR) kinase inhibitor. Gynecologic Oncology 2022, 169: 98-105. PMID: 36525930, PMCID: PMC9925406, DOI: 10.1016/j.ygyno.2022.12.003.Peer-Reviewed Original ResearchConceptsHomologous recombination deficiencyCS cell linesCell linesWestern blotKinase inhibitorsOverall animal survivalProtein expressionDose-dependent increaseDose-dependent inhibitionCarcinosarcoma cell lineTumor growth inhibitionCaspase-3 expressionEndometrioid histologyAggressive malignancyUterine carcinosarcomaCS patientsPreclinical activityClinical trialsEpithelial componentAnimal survivalXenograftsApoptosis markersRecombination deficiencyP-ATRP-Chk1
2013
Piperine inhibits the proliferation of human prostate cancer cells via induction of cell cycle arrest and autophagy
Ouyang DY, Zeng LH, Pan H, Xu LH, Wang Y, Liu KP, He XH. Piperine inhibits the proliferation of human prostate cancer cells via induction of cell cycle arrest and autophagy. Food And Chemical Toxicology 2013, 60: 424-430. PMID: 23939040, DOI: 10.1016/j.fct.2013.08.007.Peer-Reviewed Original ResearchMeSH KeywordsAlkaloidsAutophagyBenzodioxolesCell Cycle CheckpointsCell Line, TumorCell ProliferationCell SurvivalCyclin A1Cyclin D1Cyclin-Dependent Kinase Inhibitor p21Cyclin-Dependent Kinase Inhibitor p27Dose-Response Relationship, DrugDown-RegulationG1 PhaseHumansMalePiperidinesPolyunsaturated AlkamidesProstatic NeoplasmsUp-RegulationConceptsHuman prostate cancer cellsCell cycle arrestProstate cancer cellsPC-3 cellsPiperine treatmentCycle arrestCancer cellsHuman prostate cancer DU145Dose-dependent inhibitionCell linesAnti-proliferative effectsRobust cell cycle arrestGrowth inhibitory effectsLC3B puncta formationProstate cancer DU145LC3-II accumulationLNCaP cellsPresence of chloroquineCyclin D1LC3B-IILC3B punctaAntitumor mechanismAutophagy inhibitorInhibitory effectAntitumor activityD‐series resolvin attenuates vascular smooth muscle cell activation and neointimal hyperplasia following vascular injury
Miyahara T, Runge S, Chatterjee A, Chen M, Mottola G, Fitzgerald JM, Serhan CN, Conte MS. D‐series resolvin attenuates vascular smooth muscle cell activation and neointimal hyperplasia following vascular injury. The FASEB Journal 2013, 27: 2220-2232. PMID: 23407709, PMCID: PMC3659350, DOI: 10.1096/fj.12-225615.Peer-Reviewed Original ResearchConceptsD-series resolvinsVascular injuryLipid mediatorsNeointimal hyperplasiaBalloon-injured rabbit arteriesMonocyte adhesionVascular smooth muscle cell activationSuperoxide productionSmooth muscle cell activationSpecialized lipid mediatorsExpression of receptorsProinflammatory gene expressionDose-dependent inhibitionMuscle cell activationVascular smooth muscle cell phenotypeSmooth muscle cell phenotypeMuscle cell phenotypeArterial angioplastyLeukocyte recruitmentHuman VSMCsVSMC proliferationGene expression assaysRabbit arteriesVascular homeostasisRvD2
2012
Statins Inhibit Monocyte Chemotactic Protein 1 Expression in Endometriosis
Cakmak H, Basar M, Seval-Celik Y, Osteen KG, Duleba AJ, Taylor HS, Lockwood CJ, Arici A. Statins Inhibit Monocyte Chemotactic Protein 1 Expression in Endometriosis. Reproductive Sciences 2012, 19: 572-579. PMID: 22267540, PMCID: PMC3439122, DOI: 10.1177/1933719111430998.Peer-Reviewed Original ResearchConceptsCultured endometriotic cellsMonocyte chemotactic protein-1 expressionChemotactic protein-1 expressionMCP-1 productionEndometriotic cellsProtein-1 expressionEndometriotic implantsMouse modelMCP-1 messenger RNA expressionExerts anti-inflammatory effectsAnti-inflammatory effectsEffect of statinsAnti-inflammatory propertiesMCP-1 expressionMevalonate pathwayDose-dependent inhibitionNude mouse modelMessenger RNA expressionDose-dependent mannerEctopic endometriumEndometrial cellsPeritoneal surfaceStatinsPotential treatmentInhibitory effect
2011
A Metronidazole-Resistant Isolate of Blastocystis spp. Is Susceptible to Nitric Oxide and Downregulates Intestinal Epithelial Inducible Nitric Oxide Synthase by a Novel Parasite Survival Mechanism
Mirza H, Wu Z, Kidwai F, Tan KS. A Metronidazole-Resistant Isolate of Blastocystis spp. Is Susceptible to Nitric Oxide and Downregulates Intestinal Epithelial Inducible Nitric Oxide Synthase by a Novel Parasite Survival Mechanism. Infection And Immunity 2011, 79: 5019-5026. PMID: 21930763, PMCID: PMC3232666, DOI: 10.1128/iai.05632-11.Peer-Reviewed Original ResearchConceptsInducible nitric oxide synthaseMetronidazole-resistant isolatesNitric oxide synthaseNitric oxideOxide synthaseBlastocystis infectionEpithelial inducible nitric oxide synthaseST-7Dose-dependent inhibitionHost innate responseHuman intestinal epitheliumHost defense mechanismsIntestinal epithelial cellsLuminal pathogensAbdominal painIntestinal symptomsImmunocompetent patientsST-4Caco-2 modelChronic infectionControversial pathogenesisInnate responseNO productionBlastocystis sppIntestinal epithelium
2009
Phase I trial of PX-866, a novel phosphoinositide-3-kinase (PI-3K) inhibitor
Jimeno A, Hong D, Hecker S, Clement R, Kurzrock R, Pestano L, Hiscox A, Leos R, Kirkpatrick D, Eckhardt S, Herbst R. Phase I trial of PX-866, a novel phosphoinositide-3-kinase (PI-3K) inhibitor. Journal Of Clinical Oncology 2009, 27: 3542-3542. DOI: 10.1200/jco.2009.27.15_suppl.3542.Peer-Reviewed Original ResearchPX-866Stable diseaseClinical trialsDay 1Drug-related severe adverse eventsMild side effect profilePhase 1 clinical trialStabilization of diseaseSevere adverse eventsDose-limiting toxicityPhase I trialSide effect profileAdvanced metastatic cancerP-mTOR levelsDose-dependent inhibitionLower drug dosesPhosphoinositide-3 kinase inhibitorPD endpointsExpansion cohortLast doseAbdominal discomfortAdverse eventsI trialEffect profileLoss of PTENTargeting of breast cancer with non-oncology drugs – possible novel therapeutic option for triple-negative breast cancer.
Liedtke C, Yan K, Wu Y, Hortobagyi G, Symmans W, Valero V, Goette M, Kiesel L, Pusztai L. Targeting of breast cancer with non-oncology drugs – possible novel therapeutic option for triple-negative breast cancer. Cancer Research 2009, 69: 2119. DOI: 10.1158/0008-5472.sabcs-2119.Peer-Reviewed Original ResearchTriple-negative breast cancerBreast cancerTherapeutic optionsCell linesEarly-stage breast cancerHuman triple-negative breast cancerCurrent chemotherapy agentsDrug targetsReceptor-positive cancersStage breast cancerBreast cancer cell line MCF-7Future therapeutic optionsNovel therapeutic optionsCancer cell line MCF-7TNBC cell linesBreast cancer cell linesGlutathione S-transferase piFine-needle biopsyDose-dependent inhibitionLack of ERCell line MCF-7Normal HER2 expressionCancer cell linesUnique drug targetsBiological presentation
2004
Effects of oxidants and antioxidants on proliferation of endometrial stromal cells
Foyouzi N, Berkkanoglu M, Arici A, Kwintkiewicz J, Izquierdo D, Duleba AJ. Effects of oxidants and antioxidants on proliferation of endometrial stromal cells. Fertility And Sterility 2004, 82: 1019-1022. PMID: 15474067, DOI: 10.1016/j.fertnstert.2004.02.133.Peer-Reviewed Original ResearchConceptsEndometrial stromal cellsVitamin E succinateStromal cellsOxidative stressHypoxanthine/xanthine oxidaseN-acetylcysteineModest oxidative stressXanthine oxidaseDose-dependent inhibitionDiphenyl tetrazolium bromide (MTT) assayDepletion of antioxidantsEndometrial stromaTetrazolium bromide assayReproductive ageMAIN OUTCOMEPathologic conditionsThymidine incorporationIncorporation assayMTT proliferationReactive oxygen speciesBromide assayDimethylthiazol-2EndometriosisComparable findingsProliferationExpression of sigma 1 receptor in human breast cancer
Wang B, Rouzier R, Albarracin C, Sahin A, Wagner P, Yang Y, Smith T, Bernstam F, Marcelo A, Hortobagyi G, Pusztai L. Expression of sigma 1 receptor in human breast cancer. Breast Cancer Research And Treatment 2004, 87: 205-214. PMID: 15528963, DOI: 10.1007/s10549-004-6590-0.Peer-Reviewed Original ResearchConceptsHuman breast cancerSigma-1 receptorBreast cancerS1R expressionNormal breastMDA-MBCell linesBenign breast diseaseEffect of chemotherapyEpithelial cell stainingNeoplastic breast epithelial cellsInvasive breast carcinomaBreast cancer cell linesNormal breast tissueDose-dependent inhibitionAdditive cytotoxic effectBreast epithelial cellsAdjuvant chemotherapyCancer cell linesDuctal hyperplasiaMCF-7 cellsPredictive factorsCancer patientsBreast diseaseSitu cancerSmall Interfering Double-Stranded RNAs as Therapeutic Molecules to Restore Chemosensitivity to Thymidylate Synthase Inhibitor Compounds
Schmitz JC, Chen TM, Chu E. Small Interfering Double-Stranded RNAs as Therapeutic Molecules to Restore Chemosensitivity to Thymidylate Synthase Inhibitor Compounds. Cancer Research 2004, 64: 1431-1435. PMID: 14973067, DOI: 10.1158/0008-5472.can-03-1203.Peer-Reviewed Original ResearchConceptsTS expressionRKO cellsDose-dependent inhibitionCellular drug resistanceHuman colon cancer RKO cellsSynthase inhibitorColon cancer RKO cellsTherapeutic potentialDrug resistanceRNA interferenceMRNA levelsCell linesI. InhibitionProtein inductionSynthase mRNAChemosensitivityRaltitrexedDouble-stranded RNAInhibitor compoundsTherapeutic moleculesThymidylate synthase mRNATS mRNAPost-transcriptional mechanismsSiRNAEffective inhibitor
2002
Estradiol down-regulates MCP-1 expression in human coronary artery endothelial cells
Seli E, Pehlivan T, Selam B, Garcia-Velasco JA, Arici A. Estradiol down-regulates MCP-1 expression in human coronary artery endothelial cells. Fertility And Sterility 2002, 77: 542-547. PMID: 11872210, DOI: 10.1016/s0015-0282(01)03223-x.Peer-Reviewed Original ResearchConceptsHuman coronary artery endothelial cellsCoronary artery endothelial cellsMCP-1 expressionHuman umbilical vein endothelial cellsEnzyme-linked immunosorbent assayArtery endothelial cellsMCP-1 mRNAUmbilical vein endothelial cellsEndothelial cellsVein endothelial cellsMCP-1Prospective comparative studyConcentrations of estradiolMCP-1 productionMCP-1 proteinDose-dependent inhibitionVascular endothelial cellsEstrogen treatmentMacrophage recruitmentMAIN OUTCOMEMRNA expressionRibonucleic acidImmunosorbent assayProtein expressionTamoxifen
2001
Interleukin 8 production and interleukin 8 receptor expression in human myometrium and leiomyoma
Senturk L, Sozen I, Gutierrez L, Arici A. Interleukin 8 production and interleukin 8 receptor expression in human myometrium and leiomyoma. American Journal Of Obstetrics And Gynecology 2001, 184: 559-566. PMID: 11262453, DOI: 10.1067/mob.2001.111160.Peer-Reviewed Original ResearchMeSH KeywordsBlotting, NorthernCell DivisionDose-Response Relationship, DrugEnzyme-Linked Immunosorbent AssayFemaleGonadotropin-Releasing HormoneHumansImmunohistochemistryInterleukin-1Interleukin-8KineticsLeiomyomaMyometriumReceptors, Interleukin-8ARNA, MessengerTumor Cells, CulturedTumor Necrosis Factor-alphaUterine NeoplasmsConceptsInterleukin-8 productionTumor necrosis factor alphaNecrosis factor alphaInterleukin-8Factor alphaInterleukin-1alphaMyometrial cellsCell proliferationInterleukin-8 receptor expressionGonadotropin-releasing hormone agonistType APotent chemoattractant cytokinesDose-dependent increaseMyometrial cell proliferationMessenger ribonucleic acid expressionDose-dependent inhibitionEnzyme-linked immunosorbentRibonucleic acid expressionLeiomyomatous tissueLeiomyomatous uterusHormone agonistHuman myometriumReceptor expressionChemoattractant cytokinesMyometrial tissue
1999
Hepatic Toxicity and Persistence of ser/thr Protein Phosphatase Inhibition by Microcystin in the Little Skate Raja erinacea
Runnegar M, Seward D, Ballatori N, Crawford J, Boyer J. Hepatic Toxicity and Persistence of ser/thr Protein Phosphatase Inhibition by Microcystin in the Little Skate Raja erinacea. Toxicology And Applied Pharmacology 1999, 161: 40-49. PMID: 10558922, DOI: 10.1006/taap.1999.8783.Peer-Reviewed Original ResearchConceptsDose-dependent inhibitionSkate hepatocytesUptake of microcystinNear complete inhibitionPP activityInflammatory changesHepatic toxicityHepatocyte necrosisHistological changesAccompanying inhibitionHepatic lesionsBile acidsHigh dosesOnly organSignificant inhibitionSkate Raja erinaceaLittle skate Raja erinaceaInhibitionLiverRectal gland
1998
Involvement of macrophage migration inhibitory factor in the evolution of rat adjuvant arthritis
Leech M, Metz C, Santos L, Peng T, Holdsworth S, Bucala R, Morand E. Involvement of macrophage migration inhibitory factor in the evolution of rat adjuvant arthritis. Arthritis & Rheumatism 1998, 41: 910-917. PMID: 9588744, DOI: 10.1002/1529-0131(199805)41:5<910::aid-art19>3.0.co;2-e.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntibodies, MonoclonalArthritis, ExperimentalBlotting, WesternCell CountCells, CulturedDose-Response Relationship, DrugEdemaEnzyme-Linked Immunosorbent AssayImmunohistochemistryMacrophage Migration-Inhibitory FactorsMacrophagesMaleNeutralization TestsRatsRats, Sprague-DawleySynovial MembraneConceptsMacrophage migration inhibitory factorRat adjuvant arthritisAdjuvant arthritisMigration inhibitory factorSynovial macrophagesRat synoviumLevels of MIFRole of MIFInhibitory factorMonoclonal antibodiesArthritis clinical scoresT cell accumulationDose-dependent inhibitionEnzyme-linked immunosorbentMIF treatmentAdjuvant injectionMAb treatmentClinical scoresED-1Leukocyte numbersSpecific monoclonal antibodiesClinical aspectsT cellsArthritisMacrophage activation
1992
Reduction of rat liver endoplasmic reticulum Ca2+-ATPase activity and mobilization of hepatic intracellular calcium by ciprofibrate, a peroxisome proliferator
Bennett A, Williams G. Reduction of rat liver endoplasmic reticulum Ca2+-ATPase activity and mobilization of hepatic intracellular calcium by ciprofibrate, a peroxisome proliferator. Biochemical Pharmacology 1992, 43: 595-605. PMID: 1531754, DOI: 10.1016/0006-2952(92)90583-5.Peer-Reviewed Original ResearchConceptsATPase protein contentFree intracellular calcium concentrationLiver endoplasmic reticulumLiver microsomal Ca2Control levelsSingle oral doseMale F344 ratsIntracellular calcium concentrationEffect of ciprofibrateDose-dependent inhibitionControls 24 hrConcentration-dependent inhibitionEndoplasmic reticulum Ca2ATPase activityOral doseF344 ratsIntracellular calciumExtracellular calciumMicrosomal Ca2Peroxisome proliferatorTransient decreaseHepatic endoplasmic reticulumFunctional inhibitionMitogenic responseRats
1991
Effect of Silibinin on biliary lipid composition experimental and clinical study
Nassuato G, Iemmolo R, Strazzabosco M, Lirussi F, Deana R, Francesconi M, Muraca M, Passera D, Fragasso A, Orlando R, Csomós G, Okolicsányi L. Effect of Silibinin on biliary lipid composition experimental and clinical study. Journal Of Hepatology 1991, 12: 290-295. PMID: 1940257, DOI: 10.1016/0168-8278(91)90829-z.Peer-Reviewed Original ResearchConceptsBiliary lipid compositionBiliary cholesterol concentrationTotal bile salt concentrationBile salt concentrationBile flowBiliary cholesterolCholesterol concentrationsBody weightTotal liver cholesterol contentBile saturation indexSignificant dose-dependent inhibitionEffect of silymarinLiver cholesterol contentEffect of silibininDose-dependent inhibitionCoA reductase activitySilymarin treatmentLiver cholesterolPlacebo administrationCholecystectomized patientsControl ratsClinical studiesLipid compositionSilibinin doseSilibinin
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply